top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
crossref
doi
open access

Published: 07 November 2024

A Review of Covid-19 Autoimmune and Neurologic Complications

Mansoureh Fatahi, Fatemeh Refahi, Elham Derakhshan

Shahid Beheshti University of Medical Sciences (Iran), Kerman University of Medical Sciences (Iran)

journal of social and political sciences
pdf download

Download Full-Text Pdf

doi

10.31014/aior.1994.07.04.328

Pages: 48-61

Keywords: COVID-19, Immune System, Neurologic Disorders, Autoimmune Disorders

Abstract

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted the immune system. COVID-19 is considered to be linked to various autoimmune disorders. Immunologically, SARS-CoV-2 could trigger excessive inflammatory responses, leading to cytokine storms, autoimmune reactions, and dysregulation of B cell and T cell responses. These responses might contribute to different autoimmune disorders affecting different systems. Besides, the virus impacts both the central and peripheral nervous systems through a variety of neurological mechanisms. Numerous case reports and review articles have detailed the complexities arising from infection. Nonetheless, this review aims to thoroughly examine the broad spectrum of neurological and autoimmune complications linked to COVID-19 infection, emphasizing the urgent need for preventive measures and the crucial role of early detection and timely management of the complications.

References

  1. Adamec I, Brecl Jakob G, Drulović J, et al. (2022). Transverse myelitis following COVID-19: Insights from a multi-center study and systematic literature review. J Neurol Sci. 443:120463. doi:10.1016/j.jns.2022.120463

  2. Aghajanian S, Shafiee A, Akhondi A, et al. (2024). The effect of COVID-19 on Multiple Sclerosis relapse: A systematic review and meta-analysis. Mult Scler Relat Disord. 81:105128. doi:10.1016/j.msard.2023.105128

  3. Albakri A, Ah S, A A, H H. (2022). Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review. J Inflamm Res. doi:10.2147/JIR.S369477

  4. Alharbi MG, Alanazi N, Yousef A, et al. (2022). COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis. Expert Rev Hematol. doi:10.1080/17474086.2022.202969922:1.

  5. Anaya JM, Monsalve DM, Rojas M, et al. (2021). Latent rheumatic, thyroid and phospholipid autoimmunity in hospitalized patients with COVID-19. J Transl Autoimmun. 4:100091

  6. Antoon JW, Hall M, Howard LM, et al. (2022).  COVID-19 and Acute Neurologic Complications in Children. Pediatrics. 150(5):e2022058167. doi:10.1542/peds.2022-058167

  7. Aram A, A P, M G, F R.  (2021). COVID-19 and exacerbation of dermatological diseases: A review of the available literature. Dermatol Ther. 34(6). doi:10.1111/dth.15113

  8. Aref zade A. (2024). A Review of Thyroid Dysfunction Due to COVID-19. Mini Rev Med Chem. 24(3). doi:10.2174/1389557523666230413090332

  9. Assar S, M P, P S, D M. (2022).  Systemic lupus erythematosus after coronavirus disease-2019 (COVID-19) infection: Case-based review. Egypt Rheumatol. 44(2). doi:10.1016/j.ejr.2021.08.013

  10. Aydin MF, Tasdemir H, (2021). Ulcerative Colitis in a COVID-19 Patient: A Case Report. Turk J Gastroenterol. 32(6):543-547. doi:10.5152/tjg.2021.20851

  11. Azar WS, Njeim R, Fares AH, et al. (2020). COVID-19 and diabetes mellitus: how one pandemic worsens the other. Rev Endocr Metab Disord. 21(4):451-463. doi:10.1007/s11154-020-09573-6

  12. Balraj Singh, Parminder Kaur, Michael Maroules. (2021). Autoimmune Hepatitis–Primary Biliary Cholangitis Overlap Syndrome Triggered by COVID-19. Eur J Case Rep Intern Med. doi:10.12890/2021_002264

  13. Batu ED, Sener S, Ozen S. (2022). COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis. Semin Arthritis Rheum. 55:152047. doi:10.1016/j.semarthrit.2022.152047

  14. Bellia C, Andreadi A, D’Ippolito I, et al. (2023).  Prevalence and risk of new-onset diabetes mellitus after COVID-19: a systematic review and meta-analysis. Front Endocrinol. 14:1215879. doi:10.3389/fendo.2023.1215879

  15. Beshay B, K W, Q Y. (2022).  Newly diagnosed autoimmune Addison’s disease in a patient with COVID-19 with autoimmune disseminated encephalomyelitis. BMJ Case Rep. 15(12). doi:10.1136/bcr-2022-250749

  16. Bhattarai B, H A, A A, D M, K D. (2021).  Unmasking of Addison’s disease in COVID-19. SAGE Open Med Case Rep. doi:10.1177/2050313X211027758

  17. BODDU B, G A, Ms K. (2020). New onset diabetes, type 1 diabetes and COVID-19. Diabetes Metab Syndr. 14(6). doi:10.1016/j.dsx.2020.11.012

  18. Bouden S, Ben Ayed H, Rouached L, et al. (2024).  COVID-19-Induced Rheumatoid Arthritis: Case Series and Systematic Review of the Literature. Mediterr J Rheumatol. 35(2):291. doi:10.31138/mjr.171223.cir

  19. Borges B, Tm G, Bs K. (2021). Onset of dermatomyositis in close association with COVID-19-a first case reported. Rheumatol Oxf Engl. 60(SI). doi:10.1093/rheumatology/keab290

  20. Bridwell R, Long B, Gottlieb M. (2020). Neurologic complications of COVID-19. Am J Emerg Med. 38(7):1549.e3-1549.e7. doi:10.1016/j.ajem.2020.05.024

  21. Burakgazi B. (2022). Small-Fiber Neuropathy Possibly Associated with COVID-19. Case Rep Neurol. 14(1). doi:10.1159/000524205

  22. Cakir M, Guven B, Issi F, Ozkaya E. (2022).  New‐onset celiac disease in children during COVID‐19 pandemic. Acta Paediatr.111(2):383-388. doi:10.1111/apa.16173

  23. Caron P. (2020). Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. In: Vol 81. Elsevier 507-510

  24. Carroll C, V N, S C. (2023). Systemic sclerosis following COVID-19 infection with recurrent corticosteroid-induced scleroderma renal crisis. BMJ Case Rep. 16(3). doi:10.1136/bcr-2022-253735

  25. Ciaffi J, Meliconi R, Ruscitti P, Berardicurti O, Giacomelli R, Ursini F. (2020). Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC Rheumatol. 4(1):65. doi:10.1186/s41927-020-00165-0

  26. Ciaffi J, Vanni E, Mancarella L, et al. (2023). Post-Acute COVID-19 Joint Pain and New Onset of Rheumatic Musculoskeletal Diseases: A Systematic Review. Diagnostics. 13(11):1850. doi:10.3390/diagnostics13111850

  27. Chaudhary H, U N, K S, et al. (2022).  COVID-19-Associated Thrombotic Thrombocytopenic Purpura: A Case Report and Systematic Review. Hematol Rep. 14(3). doi:10.3390/hematolrep14030035

  28. Chaudhry ZS, Nellessen N, Reis C, Sharip A. (2022). The development of inflammatory arthritis following SARS-CoV-2 infection: a systematic review of the literature. Fam Pract. 39(6):1116-1134. doi:10.1093/fampra/cmac029

  29. Chen G, Wu D, Guo W, et al. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 130(5):2620. doi:10.1172/JCI137244

  30. Christensen C, M J. (2022). Association between alopecia areata and COVID-19: A systematic review. doi:10.1016/j.jdin.2022.02.002

  31. Cornea A, I L, M S, Ec R. (2023).  Parsonage-Turner Syndrome Following SARS-CoV-2 Infection: A Systematic Review. Biomedicines. 11(3). doi:10.3390/biomedicines1103083712

  32. Cunha-Silva M, França EVCD, Greca RD, et al. (2023). Autoimmune hepatitis and primary biliary cholangitis overlap syndrome after COVID-19. Autopsy Case Rep. 13:e2023422. doi:10.4322/acr.2023.422

  33. Dadras SD, R D, M A, F A. (2021).  Generalized pustular psoriasis following COVID-19. Dermatol Ther. 34(1). doi:10.1111/dth.14595

  34. Dangayach NS, Newcombe V, Sonneville R. (2022). Acute Neurologic Complications of COVID-19 and Postacute Sequelae of COVID-19. Crit Care Clin. 38(3):553-570. doi:10.1016/j.ccc.2022.03.002

  35. Durazo FA, Kristbaum K, Miller J, Saeian K, Selim M, Hong JC. (2022). De Novo Autoimmune Hepatitis after COVID-19 Infection in an Unvaccinated Patient. Vigano M, ed. Case Rep Hepatol. 2022:1-5. doi:10.1155/2022/8409269

  36. Elbadry M, Medhat MA, Zaky S, El Kassas M. (2022).  Ulcerative colitis as a possible sequela of COVID-19 Infection: The endless story. Arab J Gastroenterol. 23(2):134-137. doi:10.1016/j.ajg.2022.01.006

  37. Elhassan YS, Ronchi CL, Wijewickrama P, Baldeweg SE. (2023). Approach to the Patient With Adrenal Hemorrhage. J Clin Endocrinol Metab. 108(4):995. doi:10.1210/clinem/dgac672

  38. Fanshawe JB, Sargent BF, Badenoch JB, et al. (2024).Cognitive domains affected post‐COVID ‐19; a systematic review and meta‐analysis. Eur J Neurol. doi:10.1111/ene.16181

  39. Fineschi F. (2021). Case Report: Systemic Sclerosis After Covid-19 Infection. Front Immunol. doi:10.3389/fimmu.2021.686699

  40. Giryes S, Bragazzi NL, Bridgewood C, De Marco G, McGonagle D. (2022). COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Semin Immunopathol. 44(3):375-390. doi:10.1007/s00281-022-00928-6

  41. Hadis MH, Ss MY, R M, Fh CJ. (2022). Post-COVID-19 Dermatomyositis: A Delayed Reaction That Evades Early Detection. Medeni Med J. doi:10.4274/MMJ.galenos.2022.55890

  42. Herzum A, C M, Mf M, A P. (2022). New-onset vitiligo following COVID-19 disease. Skin Health Dis. doi:10.1002/ski2.86

  43. Hileman CO, Malakooti SK, Patil N, Singer NG, McComsey GA. (2024) . New-onset autoimmune disease after COVID-19. Front Immunol. 15:1337406. doi:10.3389/fimmu.2024.1337406

  44. Hippisley-Cox J, M P, Xw M, et al. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 374. doi:10.1136/bmj.n1931

  45. Holzer MT, Krusche M, Ruffer N, et al. (2022) .New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int. 2267-2276. doi:10.1007/s00296-022-05176-3

  46. Igbal P, F A, H C, et al.(2023).  Post-COVID-19-associated multiorgan complications or “long COVID” with literature review and management strategy discussion: A meta-analysis. Health Sci Rep. doi:10.1002/hsr2.1211

  47. Inokuchi S, Shimamoto K. (2024). Persistent Risk of Developing Autoimmune Diseases Associated With COVID-19: An Observational Study Using an Electronic Medical Record Database in Japan. JCR J Clin Rheumatol. 65-72. doi:10.1097/RHU.0000000000002054

  48. Ippolito S, Dentali F, Tanda ML. (2020). SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report. J Endocrinol Invest. 43(8):1171. doi:10.1007/s40618-020-01312-7

  49. Jackson Cody B, Farzan Michael, Chen Bing.(2022).  Mechanisms of SARS-CoV-2 entry into cells. Nature Reviews Molecular Cell Biology. https://www.nature.com/articles/s41580-021-00418-x

  50. Jacobs JW, Booth GS.(2022).  COVID-19 and Immune-Mediated RBC Destruction: A Systematic Review. Am J Clin Pathol. doi:10.1093/ajcp/aqab210

  51. Jaiswal V, Alquraish D, Sarfraz Z, et al. (2021). The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson’s Disease: An Updated Systematic Review. J Prim Care Community Health. 12:215013272110397. doi:10.1177/21501327211039709

  52. Janodia Rp, Ea K. Guttate. (2022). Psoriasis Following COVID-19 Infection. Cutis. 109(2). doi:10.12788/cutis.0443

  53. Joshi D, Gyanpuri V, Pathak A, et al.(2022). Neuropathic Pain Associated with COVID-19: a Systematic Review of Case Reports. Curr Pain Headache Rep. 26(8):595-603. doi:10.1007/s11916-022-01065-3

  54. Kabaçam G, Wahlin S, Efe C. (2021). Autoimmune hepatitis triggered by COVID‐19: A report of two cases. Liver Int. 41(10):2527-2528. doi:10.1111/liv.15044

  55. Kartsoli S, Vrakas S, Kalomoiris D, Manoloudaki K, Xourgias V. (2022). Ulcerative colitis after SARS-CoV-2 infection. Autopsy Case Rep. 12:e2021378. doi:10.4322/acr.2021.378

  56. Kasmikha K, M M, S G, S K, J A. (2023). Vitiligo Following COVID-19 Vaccination and Primary Infection: A Case Report and Systematic Review. Cureus. 15(9). doi:10.7759/cureus.45546

  57. Kempuraj D, Aenlle KK, Cohen J, et al. (2024). COVID-19 and Long COVID: Disruption of the Neurovascular Unit, Blood-Brain Barrier, and Tight Junctions. The Neuroscientist. 30(4):421-439. doi:10.1177/10738584231194927

  58. Kim K, Hy K. (2023). Pemphigus Vulgaris Possibly Associated with COVID-19 Infection. Cureus. 15(1). doi:10.7759/cureus.33897

  59. Kim K, Kim S yeon, Kim YE, Kwon KW, Han EM, Kim A. (2023). Two Case Reports of Newly Diagnosed Crohn’s Disease after COVID-19 in Pediatric Patients. Korean J Gastroenterol. 81(4):163-167. doi:10.4166/kjg.2022.14

  60. Kouranloo K, Dey M, Elwell H, Nune A. (2023). A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19. Rheumatol Int. 43(7):1221-1243. doi:10.1007/s00296-023-05283-9

  61. Lee J, Seo GH, Song K. (2023). Beyond acute COVID-19: investigating the incidence of subacute thyroiditis in long COVID-19 in Korea. Endocrinol Metab. 38(4):455-461. Doi:10.3803/enm.2023.1711

  62. Lexner J, Lindroth Y, Sjöberg K. (2023). The risk for celiac disease after Covid-19 infection. BMC Gastroenterol. 23(1):174. doi:10.1186/s12876-023-02795-3

  63. Li C, He Q, Qian H, Liu J.(2021). Overview of the pathogenesis of COVID-19 (Review). Exp Ther Med. 22(3). doi:10.3892/etm.2021.10444

  64. Li C, Verduzco-Gutierrez M. (2023). Neurologic and Neuromuscular Sequelae of COVID-19. Phys Med Rehabil Clin N Am. 34(3):539-549. doi:10.1016/j.pmr.2023.04.002

  65. Lim SH, Ju HJ, Han JH, et al. (2023). Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19. JAMA . 6(10):e2336120-e2336120. doi:10.1001/jamanetworkopen.2023.36120

  66. Lodigiani L, G I, L C, et al. (2020). Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. doi:10.1016/j.thromres.2020.04.024

  67. Lotan I, Nishiyama S, Manzano GS, Lydston M, Levy M. (2022).COVID-19 and the risk of CNS demyelinating diseases: A systematic review. Front Neurol. doi:10.3389/fneur.2022.970383

  68. Lui DT, Lee CH, Chow WS, et al. (2021). Insights from prospective follow-up of thyroid function and autoimmunity among covid-19 survivors. J Endocr Soc. 5(Supplement_1):A840-A841. doi: 10.3803/EnM.2021.983

  69. Luo W, Liu X, Bao K, Huang C. (2022). Ischemic stroke associated with COVID-19: a systematic review and meta-analysis. J Neurol. 269(4):1731-1740. doi:10.1007/s00415-021-10837-7

  70. Lupu A, Miron IC, Gavrilovici C, et al. (2023). Pediatric Systemic Lupus Erythematous in COVID-19 Era. Viruses. 15(2):272. doi:10.3390/v15020272

  71. Mahmoud H, Alhathla A, El-Fiky A, et al. (2023). Incidence of Guillain-Barré Syndrome post COVID-19: a systematic review of case reports and case series. Eur Rev Med Pharmacol Sci. 27(5):2152-2164. doi:10.26355/eurrev_202303_31588

  72. Manzano GS, McEntire CRS, Martinez-Lage M, Mateen FJ, Hutto SK. (2021). Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19: Systematic Review and Meta-synthesis. Neurol Neuroimmunol Neuroinflammation. doi:10.1212/NXI.0000000000001080

  73. Mao L, H J, M W, et al. (2020). Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 77(6). doi:10.1001/jamaneurol.2020.1127

  74. Martini N, Singla P, Arbuckle E, et al. (2023). SARS-CoV-2-Induced Autoimmune Hepatitis. Cureus. doi:10.7759/cureus.38932

  75. Medeiros DM, Au MN, Ddt F, R CB, Éo de MC, Dm T. (2021). Pemphigus Vulgaris After COVID-19: a Case of Induced Autoimmunity. SN Compr Clin Med. 3(8).doi:10.1007/s42399-021-00971-8

  76. Messova A, Pivina L, Muzdubayeva Z, Sanbayev D, Urazalina Z, Adams A. (2022).  COVID-19 and New Onset IgA Vasculitis: A Systematic Review of Case Reports. J Emerg Nurs. 48(4):348-365. doi:10.1016/j.jen.2022.05.002

  77. Migliorini F, Bell A, Vaishya R, Eschweiler J, Hildebrand F, Maffulli N. (2023). Reactive arthritis following COVID-19 current evidence, diagnosis, and management strategies. J Orthop Surg. 18(1):205. doi:10.1186/s13018-023-03651-6

  78. Montes HM, C F de LP, D FP, et al. (2022). Prevalence of Neuropathic Component in Post-COVID Pain Symptoms in Previously Hospitalized COVID-19 Survivors. Int J Clin Pract. doi:10.1155/2022/3532917

  79. Mostafavi M, Abraham A, Mueller J, Sayej W. (2023).  Concurrent, New-Onset Autoimmune Hepatitis, Celiac Disease, and Hashimoto’s Thyroiditis Following COVID-19: A Case Report. JPGN Rep. 4(4):e388. doi:10.1097/PG9.0000000000000388

  80. Mudge HR, Honey JR, Tachoukaft S, et al. (2024). Summarizing Evidence of Associations of COVID‐19 With a Future Diagnosis of Inflammatory Rheumatic and Musculoskeletal Diseases: A Rapid Review. Arthritis Care Res. 76(1):40-48. doi:10.1002/acr.25227

  81. Mushtaq Mz, Sb ZM, Sa A, Mu S. (2023).  COVID-19 and thrombotic thrombocytopenic purpura: A case report. JPMA J Pak Med Assoc. 73(2). doi:10.47391/JPMA.4992

  82. Neophytou P, Artemiadis A, Hadjigeorgiou GM, Zis P. (2023). Miller Fischer syndrome after COVID-19 infection and vaccine: a systematic review. Acta Neurol Belg. 123(5):1693-1701. doi:10.1007/s13760-023-02336-5

  83. Nguyen N, A T. Alopecia in patients with COVID-19: (2022). A systematic review and meta-analysis. JAAD Int. doi:10.1016/j.jdin.2022.02.006

  84. Odozor CU, Kannampallil T, Ben Abdallah A, et al. (2022). Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study. Pain. 163(12):2398-2410. doi:10.1097/j.pain.0000000000002639

  85. Olson O, Jl C, Sd M. (2001). Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol. 14(3). doi:10.1089/088282401753266756

  86. Ono R, I K. (2024). SARS-CoV-2 infection-induced immune thrombocytopenia: a systematic review of current reports. Ann Hematol. doi:10.1007/s00277-024-05765-1

  87. Ortega QO, A R, M R de V, et al. (2021). Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report. Mod Rheumatol Case Rep. doi:10.1080/24725625.2020.1832755

  88. Pastukhova P, Fm G. (2024). New-onset of pemphigus following COVID-19 infection: A case report. SAGE Open Med Case Rep. doi:10.1177/2050313X241231423

  89. Pinzon Rt, Vo W, Aa J, Pn N, Rb B. (2022).  Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis. J Infect Public Health. doi:10.1016/j.jiph.2022.06.013

  90. Perrottelli A, Sansone N, Giordano GM, et al. (2022). Cognitive Impairment after Post-Acute COVID-19 Infection: A Systematic Review of the Literature. J Pers Med. 12(12):2070. doi:10.3390/jpm12122070

  91. Pimentel V, Luchsinger VW, Carvalho GL, et al. (2023). Guillain–Barré syndrome associated with COVID-19: A systematic review. Brain Behav Immun - Health. 28:100578. doi:10.1016/j.bbih.2022.100578

  92. Poyiadji P, G S, D N, M S, S P, B G. (2020). COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. Radiology. 296(2). doi:10.1148/radiol.2020201187

  93. RAHMATI R, Dk Y, Sw L, et al. (2023). New-onset type 1 diabetes in children and adolescents as postacute sequelae of SARS-CoV-2 infection: A systematic review and meta-analysis of cohort studies. J Med Virol. 95(6). doi:10.1002/jmv.28833

  94. Rehman MAU, Farooq H, Ali MM, Rehman MEU, Dar QA, Hussain A. (2021). The Association of Subacute Thyroiditis with COVID-19: a Systematic Review. Sn Compr Clin Med. 3(7):1515. doi:10.1007/s42399-021-00912-5

  95. Sacchi MC, Tamiazzo S, Stobbione P, et al. (2021).  SARS‐CoV‐2 infection as a trigger of autoimmune response. Clin Transl Sci. 14(3):898. doi:10.1111/cts.12953

  96. Sachdeva M, Agarwal A, Sra HK, et al. (2022). Multisystem Inflammatory Syndrome Associated With COVID-19 in Children (MIS-C): A Systematic Review of Studies From India. Indian Pediatr. 59(7):563-569. doi:10.1007/s13312-022-2559-5

  97. Sanchez S, M C, Jl Z, Y E. (2022). Primary Adrenal Insufficiency After COVID-19 Infection. AACE Clin Case Rep. 8(2). doi:10.1016/j.aace.2021.11.001

  98. Schulte Ec, L H, Ab K, J S. (2021). Systematic review of cases of acute myelitis in individuals with COVID-19. Eur J Neurol. 28(10). doi:10.1111/ene.14952

  99. Sedaghat S, N K. (2020). Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci SOff J Neurosurg Soc Australas. doi:10.1016/j.jocn.2020.04.062

  100. Senthamizhselvan K, Ramalingam R, Mohan P, Kavadichanda C, Badhe B, Hamide A. (2021). De Novo Crohn’s Disease Triggered After COVID-19: Is COVID-19 More Than an Infectious Disease? ACG Case Rep J. 8(8):e00652. doi:10.14309/crj.0000000000000652

  101. Seyedmirzaei H, Salabat D, KamaliZonouzi S, Teixeira AL, Rezaei N. (2024). Risk of MS relapse and deterioration after COVID-19: A systematic review and meta-analysis. Mult Scler Relat Disord. 83:105472. doi:10.1016/j.msard.2024.105472

  102. Sharma D, Bhaskar SMM. (2022). Prevalence of paediatric hyperinflammatory conditions in paediatric and adolescent hospitalized COVID‐19 patients: a systematic review and meta‐analysis. APMIS. 130(2):101-110. doi:10.1111/apm.13199

  103. Sheikh , Rm ES, S S, Ak S, Jg T. (2010). Activation of B cells by antigens on follicular dendritic cells. Trends Immunol. 31(6). doi:10.1016/j.it.2010.03.002

  104. Shrestha DB, Budhathoki P, Raut S, et al. (2021).  New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. 10(5):275-287. doi:10.5501/wjv.v10.i5.275

  105. Stathi D, Triantafyllidis KK, Zafeiri M, Karalliedde J, Kechagias KS. (2023). COVID-19 induced type 1 diabetes: A systematic review of case reports and series. J Int Med Res. 51(11):03000605231210403. doi:10.1177/03000605231210403

  106. Stefano DS, P F, E G, G DP, C L, A T. (2023). A systematic review and meta-analysis of neuropathic pain associated with coronavirus disease 2019. Eur J Pain Lond Engl. 27(1). doi:10.1002/ejp.2055

  107. Stoermer K, Te M. (2011). Complement and viral pathogenesis. Virology. 411(2). doi:10.1016/j.virol.2010.12.045

  108. Syed U, Subramanian A, Wraith DC, et al. (2023). Incidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care. BMC Med. 21(1):363. doi:10.1186/s12916-023-03049-5

  109. Taherianfard E, H M, Mr M. (2021).  Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. Hematol Amst Neth. 26(1). doi:10.1080/16078454.2021.1881225

  110. Tavares-Júnior JWL, De Souza ACC, Borges JWP, et al. (2022). COVID-19 associated cognitive impairment: A systematic review. Cortex. 152:77-97. doi:10.1016/j.cortex.2022.04.006

  111. Taxonera C, Fisac J, Alba C. Can COVID-19 (2021). Trigger De Novo Inflammatory Bowel Disease? Gastroenterology. 160(4):1029-1030. doi:10.1053/j.gastro.2020.11.026

  112. Tehrani HA, Darnahal M, Vaezi M, Haghighi S. (2021). COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review. Int Immunopharmacol. 2021;93:107397. doi:10.1016/j.intimp.2021.107397

  113. Tursi A, Nenna R. (2022). COVID-19 as a Trigger for De Novo Crohn’s Disease. Inflamm Bowel Dis. 28(6):e76-e77. doi:10.1093/ibd/izab298

  114. Tutal T, R O, H L. (2022). Systematic review of COVID-19 and autoimmune thyroiditis. Travel Med Infect Dis. 47. doi:10.1016/j.tmaid.2022.102314

  115. Vamshidhar V, Sss R, M K, et al. (2023). Impact of COVID-19 on thyroid gland functions with reference to Graves’ disease: A systematic review. J Fam Med Prim Care. 12(9). doi:10.4103/jfmpc.jfmpc_2246_22

  116. Vahabi M, T G, S S. (2022).  Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. Int Immunopharmacol. 112. doi:10.1016/j.intimp.2022.109183

  117. Vigilizzo V, A H, L G, C O, C O. (2023). Childhood vitiligo developing after COVID-19 infection. Dermatol Rep. 15(3). doi:10.4081/dr.2023.9547

  118. Volchkova EA, Legkova KS, Topchy TB. (2022). COVID-19 as a trigger of autoimmune hepatitis. Case report. Ter Arkh. 94(2):259-264. doi:10.26442/00403660.2022.02.201374

  119. Wong C K, Lam C W K, Wu A K L, (2004). Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome | Oxford Academic. Clin Exp Immunol. Apr;136(1):95–103. doi: 10.1111/j.1365-2249.2004.02415.x

  120. Wong K, Farooq Alam Shah MU, Khurshid M, Ullah I, Tahir MJ, Yousaf Z. (2022).  COVID-19 associated vasculitis: A systematic review of case reports and case series. Ann Med Surg. 74. doi:10.1016/j.amsu.2022.103249

  121. Xie X, M Y, P Z, J F, S Z. (2023). New-onset pemphigus foliaceus after COVID-19 infection. J Med Virol. 95(6). doi:10.1002/jmv.28867

  122. Yassin A, Nawaiseh M, Shaban A, et al. (2021). Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. BMC Neurol. 21(1):138. doi:10.1186/s12883-021-02161-4

  123. Yazdanpanah N, Rezaei N. (2022). Autoimmune complications of COVID‐19. J Med Virol. 94(1):54. doi:10.1002/jmv.27292

  124. Yu Y, F Y, F L, Z D, L D. (2023(. A Sjögren’s syndrome patient rapidly progressed to scleroderma renal crisis after COVID-19 infection. Rheumatol Adv Pract. 8(1). doi:10.1093/rap/rkad107

  125. Zelada-Ríos L, Pacheco-Barrios K, Galecio-Castillo M, Yamunaqué-Chunga C, Álvarez-Toledo K, Otiniano-Sifuentes R. (2021). Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases. J Neuroimmunol. doi:10.1016/j.jneuroim.2021.577674

  126. Zhou SY, Zhang C, Shu WJ, et al. (2021). Emerging Roles of Coronavirus in Autoimmune Diseases. Arch Med Res. 52(7):665. doi:10.1016/j.arcmed.2021.03.012

  127. Zou Z, S D. (2022). Pemphigus vulgaris after COVID-19 infection and vaccination. J Am Acad Dermatol. 87(3). doi:10.1016/j.jaad.2022.05.013

  128. Zou Z, A R, S D. (2023). Scleroderma after COVID-19 Infection and Vaccination. Skinmed. 2023;21(4). https://pubmed.ncbi.nlm.nih.gov/37771015

bottom of page